Fig. 3From: Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrenceModulation of costimulatory and coregulatory molecules by iv-SIL. PBMC were analyzed before (pre) and after (post) iv-SIL treatment by flow cytometry, as described in the “Methods” section. Overall analyses of significantly modified markers on mDC (a ICOSL) and pDC (b HLA-DR MFI, c HLA-G %, d ILT4 MFI, e CD39 %, and f CD39 MFI) are shownBack to article page